The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Utility of ctDNA burden as a prognostic biomarker for efficacy in TALAPRO-2: A phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
 
Arun Azad
Honoraria - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Consulting or Advisory Role - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Novartis
Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma; Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hinova Pharmaceuticals (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono; Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Synthorx (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bayer; Hinova Pharmaceuticals; Janssen; Merck Serono; Pfizer; Sanofi; Tolmar
 
Karim Fizazi
Honoraria - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst)
Consulting or Advisory Role - Amgen (Inst); Arvinas; Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); CureVac; Daiichi Sankyo Europe GmbH (Inst); Janssen Oncology (Inst); Macrogenics; MSD (Inst); Novartis (Inst); Orion; Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; MSD; Pfizer
 
Douglas Laird
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Nobuaki Matsubara
Honoraria - Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Janssen; Lilly; Pfizer; Sanofi; Seagen
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Eisai (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst)
 
Ugo De Giorgi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Dompé Farmaceutici; Eisai; Ipsen; Janssen; Merck; MSD; Novartis; Pfizer; PharmaMar
Research Funding - AstraZeneca (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca/Daiichi Sankyo; Ipsen; Merck; Pfizer
 
Consuelo ButtIgliero
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen-Cilag; Merck; MSD
 
Lawrence Ivan Karsh
Stock and Other Ownership Interests - Swan Medical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Dendreon; Janssen; Merck; Pfizer; Sanofi
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Dendreon; Janssen; Lantheus Medical Imaging; Merck; Pfizer
Research Funding - Astellas Pharma; Bayer; BMS GmbH & Co. KG; Dendreon; FKD Therapies; Janssen; KDx Diagnostics; Myovant Sciences; Neuspera; OncoCellMDx; Pfizer; Tavanta Therapeutics
 
Jae Young Joung
Honoraria - Astellas Pharma; Johnson & Johnson/Janssen; Sanofi/Aventis
 
Steven Yip
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck; Novartis; OncoHelix; Pfizer; Roche
 
Stefanie Zschaebitz
Honoraria - Amgen; Astellas Pharma; Bayer; BMS GmbH & Co. KG; Eisai Germany; Ipsen; Janssen Oncology; Merck Serono; MSD Oncology; Novartis; Pfizer (Inst)
Consulting or Advisory Role - Amgen; Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai; EUSA Pharma; Gilead Sciences; Ipsen; Merck; MSD Oncology; Pfizer (Inst); Roche; Sanofi/Aventis (Inst)
Research Funding - Eisai (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; BMS GmbH & Co. KG; Ipsen; Janssen Oncology; Merck; Pfizer
 
Lee A. Albacker
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Cynthia G. Healy
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Xun Lin
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Jijumon Chelliserry
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Neeraj Agarwal
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Exelixis; Pfizer